We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

002414:SZSEWuhan Guide Infrared Co., Ltd. Analysis

Data as of 2026-07-27 - not real-time

CN¥14.36

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Wuhan Guide Infrared is trading near the upper end of its 52‑week range at CNY 14.36, just below the recent high of CNY 14.95 and above its 20‑day SMA of 13.34. The stock shows a bullish MACD histogram (+0.10) and rising volume, suggesting short‑term upward momentum, yet the PE ratio of roughly 62× dwarfs the industry average of 33×, flagging significant overvaluation. Revenue has surged 83% year‑over‑year and margins remain healthy (gross ~56%, operating ~35%), but the DCF‑derived fair value of about CNY 1.26 starkly contradicts the current price, underscoring a valuation disconnect. With a beta under 0.5, the share exhibits low systematic risk, but 30‑day volatility exceeds 60%, indicating price swings can be sharp. No dividend is paid, so income‑focused investors have no yield cushion.
Overall, the company’s strong growth fundamentals are weighed against an extreme premium, making it a speculative play that may benefit from continued sector tailwinds in infrared and AIOT applications, but also vulnerable to a correction if sentiment shifts.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD and increasing volume support near‑term upside
  • Current price just below recent resistance level
  • Extreme valuation premium raises downside risk

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Robust revenue growth and strong operating margins
  • Valuation remains far above peers and DCF fair value
  • Moderate beta and solid liquidity mitigate systemic shocks

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Sustained demand for infrared and AIOT technologies in China and abroad
  • High ROE (~14%) and positive free cash flow indicate durable profitability
  • Potential for valuation re‑rating if market sentiment normalises

Key Metrics & Analysis

Financial Health

Revenue Growth83.00%
Profit Margin18.68%
P/E Ratio62.4
ROE14.01%
ROA7.79%
Debt/Equity4.53
P/B Ratio8.3
Op. Cash FlowCN¥1.5B
Free Cash FlowCN¥151.3M
Industry P/E32.9

Technical Analysis

TrendNeutral
RSI57.8
SupportCN¥12.07
ResistanceCN¥14.95
MA 20CN¥13.34
MA 50CN¥13.32
MA 200CN¥13.95
MACDBullish
VolumeIncreasing
Fear & Greed Index88.25

Valuation

Fair ValueCN¥1.26
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.44
Volatility61.68%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.